What is the current market price reference for Datopotamab?

Datopotamab deruxtecan (trade name Datroway) is an antibody drug conjugate (ADC) used to treat advanced non-small cell lung cancer (NSCLC). As a new type of targeted drug, it combines antibodies with cytotoxic drugs to accurately kill tumor cells and significantly improve the therapeutic effect. The drug has been approved in many countries including the United States for use in patients who have previously received systemic therapy.

Currently, dabrotuzumab is priced relatively high in the US market. According to public data, the price of an injection of 100 mg is approximately US$5,200. Since the dosage and course of treatment are different for each patient, the overall cost of treatment will vary greatly. Based on common treatment dosage estimates, the cost of a course of treatment may reach tens of thousands of dollars, which is relatively expensive.

In addition to clinical drugs, there are also small packaged versions on the market for scientific research purposes, with prices ranging from hundreds to thousands of dollars per milligram. These products are mainly used for laboratory research and are not suitable for direct use by patients. Patients should pay attention to the formal sources and uses of drugs when purchasing and using them, and avoid misuse of scientific research-grade products.

Overall, dabrotomab, as an emerging targeted tumor treatment drug, is relatively expensive but has significant efficacy. When using it, patients should consider their own financial situation and doctor's advice to plan a reasonable treatment plan. At the same time, some countries and regions provide patient assistance programs to help alleviate financial pressure and improve patients’ medication accessibility.

Reference materials:https://www.drugs.com/